A study of 5 years of adjuvant osimertinib in completely resected epidermal growth factor receptor mutation (EGFRm) non-small cell lung carcinoma (NSCLC)

Trial Identifier: D5162C00048
Sponsor: AstraZeneca
Start Date: March 2023
Primary Completion Date: November 2029
Study Completion Date: November 2029

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
ES Badalona, ES, 08013
ES Barcelona, ES, 08036
ES Bilbao, ES, 48013
ES Granada, ES, 18014
ES L'Hospitalet de Llobregat, ES, 08907
ES Madrid, ES, 28007
ES Sevilla, ES, 41009
ES Valencia, ES, 46026
GB London, GB, SW3 6JJ
GB NOTTINGHAM, GB, NG5 1PB
HK Hong Kong, HK
HK Hong Kong, HK, 150001
HK Hong Kong, HK, 999077
IT Avellino, IT, 83100
IT Brescia, IT, 25123
IT Lecce, IT, 73100
IT Milano, IT, 20141
IT NAPOLI, IT, 80131
IT Palermo, IT, 90146
IT PESCHIERA DEL GARDA, IT, 37019
IT Reggio Emilia, IT, 42123
IT Sondrio, IT, 23100
IT Terni, IT, 05100
IT Udine, IT, 33100
KR Busan, KR, 48108
KR Busan, KR, 49241
KR Cheongju-si, KR, 28644
KR Daejeon, KR, 35015
KR Goyang-si, KR, 410-769
KR Gyeonggi-do, KR, 13620
KR Incheon, KR, 21565
KR Seongnam-si, KR, 13496
KR seoul, KR, 06351
KR Seoul, KR, 03080
KR Seoul, KR, 03722
KR Seoul, KR, 05505
KR Seoul, KR, 05030
KR Seoul, KR, 06273
KR Seoul, KR, 06591
MY Kuala Lumpur, MY, 59100
MY Kuantan, MY, 25100
MY Kuching, MY, 93586
PH Cebu, PH, 6000
PH Manila, PH, 1000
PH Quezon City, PH, 1100
SG Singapore, SG, 119074
TH Bangkok, TH, 10700
TH Songkhla, TH, 90110
TW Hualien, TW, 970
TW Kaohsiung, TW, 82445
TW Kaohsiung, TW, 833401
TW Taichung, TW, 40705
TW Taipei, TW, 10449
US, CA Santa Rosa, CA, US, 95403
US, NV Las Vegas, NV, US, 89169
US, NY White Plains, NY, US, 10601